Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note issued on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

NASDAQ:BCLI opened at $1.35 on Wednesday. The company has a market capitalization of $7.70 million, a price-to-earnings ratio of -0.28 and a beta of 0.74. Brainstorm Cell Therapeutics has a 1-year low of $1.05 and a 1-year high of $11.25. The business has a 50 day moving average of $1.73 and a 200 day moving average of $2.05.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.